These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18479610)

  • 1. [Research progress on basal-like breast cancer].
    Chen LY; Chen HF
    Ai Zheng; 2008 May; 27(5):555-8. PubMed ID: 18479610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
    Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
    Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic features and immunohistochemistry of the basal-like subtype of invasive breast carcinoma].
    Liu LP; Bai J; Wei Y; Qi XD; Si TC; Li W; Pan H
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):101-5. PubMed ID: 23710916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
    Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
    Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
    Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
    Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
    Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
    Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
    Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
    Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of basal phenotype in HER2-overexpressing breast cancer.
    Bagaria SP; Ray PS; Wang J; Kropcho L; Chung A; Sim MS; Shamonki JM; Martino S; Cui X; Giuliano AE
    Ann Surg Oncol; 2012 Mar; 19(3):935-40. PubMed ID: 21879270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients.
    Ben Abdelkrim S; Trabelsi A; Missaoui N; Beizig N; Bdioui A; Anjorin A; Jomaa W; Mokni M
    Pathol Res Pract; 2010 Nov; 206(11):772-5. PubMed ID: 20850937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
    Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers.
    Mujtaba SS; Ni YB; Tsang JY; Chan SK; Yamaguchi R; Tanaka M; Tan PH; Tse GM
    Ann Surg Oncol; 2013 Sep; 20(9):2842-9. PubMed ID: 23539156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.